Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures

Oula Dagher; Tiffany R King; Nils Wellhausen; Avery D Posey Jr

doi:10.1016/j.ccell.2020.10.003

Combination Therapy for Solid Tumors: Taking a Classic CAR on New Adventures

Cancer Cell. 2020 Nov 9;38(5):621-623. doi: 10.1016/j.ccell.2020.10.003. Epub 2020 Oct 15.

Authors

Oula Dagher¹, Tiffany R King¹, Nils Wellhausen¹, Avery D Posey Jr²

Affiliations

¹ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. Electronic address: aposey@pennmedicine.upenn.edu.

PMID: 33064993
DOI: 10.1016/j.ccell.2020.10.003

Abstract

CD19-specific CAR-T cell therapies are the gold standard of adoptive cellular immunotherapy for hematopoietic malignancies. In Science Translational Medicine, Park et al. develop an oncolytic vaccinia virus that introduces truncated CD19 expression in solid tumors, which are then eradicated by CD19-specific CAR-T cells in immunodeficient and immunocompetent mouse models.

Published by Elsevier Inc.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Antigens, CD19
Immunotherapy
Immunotherapy, Adoptive
Mice
Neoplasms* / therapy
Oncolytic Viruses*
T-Lymphocytes / immunology

Substances

Antigens, CD19